Iranian Red Crescent Medical Journal

Published by: Kowsar

Effect of Serum Hepcidin on Predicting Mortality in Hemodialysis Patients: A Prospective Cohort Study

Ling Sun 1 , * , Lu-Xi Zou 2 , Yan Lu 1 , Na Deng 1 and Hui-Xin Wang 1
Authors Information
1 Department of Nephrology, Xuzhou Central Hospital, Xuzhou Medical University, Xuzhou, China
2 Zhejiang University, Hangzhou, China
Article information
  • Iranian Red Crescent Medical Journal: 21 (3); e87091
  • Published Online: March 13, 2019
  • Article Type: Research Article
  • Received: December 5, 2018
  • Revised: February 22, 2019
  • Accepted: February 25, 2019
  • DOI: 10.5812/ircmj.87091

To Cite: Sun L, Zou L, Lu Y, Deng N, Wang H. Effect of Serum Hepcidin on Predicting Mortality in Hemodialysis Patients: A Prospective Cohort Study, Iran Red Crescent Med J. Online ahead of Print ; 21(3):e87091. doi: 10.5812/ircmj.87091.

Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. NKF-KDIGO Guideline Development Staff. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2(4):279-335.
  • 2. Gaweda AE. Markers of iron status in chronic kidney disease. Hemodial Int. 2017;21 Suppl 1:S21-7. doi: 10.1111/hdi.12556. [PubMed: 28328097]. [PubMed Central: PMC6247786].
  • 3. Wish JB, Aronoff GR, Bacon BR, Brugnara C, Eckardt KU, Ganz T, et al. Positive iron balance in chronic kidney disease: How much is too much and how to tell? Am J Nephrol. 2018;47(2):72-83. doi: 10.1159/000486968. [PubMed: 29439253].
  • 4. Ueda N, Takasawa K. Impact of inflammation on ferritin, hepcidin and the management of iron deficiency anemia in chronic kidney disease. Nutrients. 2018;10(9). doi: 10.3390/nu10091173. [PubMed: 30150549]. [PubMed Central: PMC6163440].
  • 5. Poli M, Asperti M, Ruzzenenti P, Regoni M, Arosio P. Hepcidin antagonists for potential treatments of disorders with hepcidin excess. Front Pharmacol. 2014;5:86. doi: 10.3389/fphar.2014.00086. [PubMed: 24808863]. [PubMed Central: PMC4009444].
  • 6. Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 2009;75(9):976-81. doi: 10.1038/ki.2009.21. [PubMed: 19212416].
  • 7. Ford BA, Eby CS, Scott MG, Coyne DW. Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients. Kidney Int. 2010;78(8):769-73. doi: 10.1038/ki.2010.254. [PubMed: 20668427].
  • 8. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood. 2008;112(10):4292-7. doi: 10.1182/blood-2008-02-139915. [PubMed: 18689548].
  • 9. Ueda N, Takasawa K. Role of hepcidin-25 in chronic kidney disease: Anemia and beyond. Curr Med Chem. 2017;24(14):1417-52. doi: 10.2174/0929867324666170316120538. [PubMed: 28302014].
  • 10. Kali A, Yayar O, Erdogan B, Eser B, Buyukbakkal M, Ercan Z, et al. Is hepcidin-25 a predictor of atherosclerosis in hemodialysis patients? Hemodial Int. 2016;20(2):191-7. doi: 10.1111/hdi.12355. [PubMed: 26374145].
  • 11. Rostoker G, Vaziri ND. Iatrogenic iron overload and its potential consequences in patients on hemodialysis. Presse Med. 2017;46(12 Pt 2):e312-28. doi: 10.1016/j.lpm.2017.10.014. [PubMed: 29153377].
  • 12. Yayar O, Eser B, Kilic H. Relation between high serum hepcidin-25 level and subclinical atherosclerosis and cardiovascular mortality in hemodialysis patients. Anatol J Cardiol. 2018;19(2):117-22. doi: 10.14744/AnatolJCardiol.2017.8019. [PubMed: 29339674]. [PubMed Central: PMC5864805].
  • 13. Vela D. Balance of cardiac and systemic hepcidin and its role in heart physiology and pathology. Lab Invest. 2018;98(3):315-26. doi: 10.1038/labinvest.2017.111. [PubMed: 29058707].
  • 14. Tessitore N, Girelli D, Campostrini N, Bedogna V, Pietro Solero G, Castagna A, et al. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol Dial Transplant. 2010;25(12):3996-4002. doi: 10.1093/ndt/gfq321. [PubMed: 20538788].
  • 15. Gaillard CA, Bock AH, Carrera F, Eckardt KU, Van Wyck DB, Bansal SS, et al. Hepcidin response to iron therapy in patients with non-dialysis dependent CKD: An analysis of the FIND-CKD trial. PLoS One. 2016;11(6). e0157063. doi: 10.1371/journal.pone.0157063. [PubMed: 27276035]. [PubMed Central: PMC4898697].
  • 16. Petruliene K, Ziginskiene E, Kuzminskis V, Nedzelskiene I, Bumblyte IA. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in hemodialysis patients. Medicina (Kaunas). 2017;53(2):90-100. doi: 10.1016/j.medici.2017.03.001. [PubMed: 28416170].
  • 17. Daugirdas JT. Kt/V (and especially its modifications) remains a useful measure of hemodialysis dose. Kidney Int. 2015;88(3):466-73. doi: 10.1038/ki.2015.204. [PubMed: 26176827].
  • 18. Suttorp MM, Hoekstra T, Rotmans JI, Ott I, Mittelman M, Krediet RT, et al. Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients. BMC Nephrol. 2013;14:200. doi: 10.1186/1471-2369-14-200. [PubMed: 24066978]. [PubMed Central: PMC3849281].
  • 19. Lee SW, Kim YH, Chung W, Park SK, Chae DW, Ahn C, et al. Serum hepcidin and iron indices affect anemia status differently according to the kidney function of non-dialysis chronic kidney disease patients: Korean cohort study for outcome in patients with chronic kidney disease (KNOW-CKD). Kidney Blood Press Res. 2017;42(6):1183-92. doi: 10.1159/000485865. [PubMed: 29227972].
  • 20. Slotki I, Cabantchik ZI. The labile side of iron supplementation in CKD. J Am Soc Nephrol. 2015;26(11):2612-9. doi: 10.1681/ASN.2015010052. [PubMed: 25999405]. [PubMed Central: PMC4625683].
  • 21. Mikhail A, Brown C, Williams JA, Mathrani V, Shrivastava R, Evans J, et al. Renal association clinical practice guideline on anaemia of chronic kidney disease. BMC Nephrol. 2017;18(1):345. doi: 10.1186/s12882-017-0688-1. [PubMed: 29191165]. [PubMed Central: PMC5709852].
  • 22. Vyoral D, Jiri P. Therapeutic potential of hepcidin - the master regulator of iron metabolism. Pharmacol Res. 2017;115:242-54. doi: 10.1016/j.phrs.2016.11.010. [PubMed: 27867027].
  • 23. Nairz M, Theurl I, Wolf D, Weiss G. Iron deficiency or anemia of inflammation? Differential diagnosis and mechanisms of anemia of inflammation. Wien Med Wochenschr. 2016;166(13-14):411-23. doi: 10.1007/s10354-016-0505-7. [PubMed: 27557596]. [PubMed Central: PMC5065583].
  • 24. Ogawa C, Tsuchiya K, Tomosugi N, Kanda F, Maeda K, Maeda T. Low levels of serum ferritin and moderate transferrin saturation lead to adequate hemoglobin levels in hemodialysis patients, retrospective observational study. PLoS One. 2017;12(6). e0179608. doi: 10.1371/journal.pone.0179608. [PubMed: 28662118]. [PubMed Central: PMC5491034].
  • 25. Haghpanah S, Esmaeilzadeh M, Honar N, Hassani F, Dehbozorgian J, Rezaei N, et al. Relationship between serum hepcidin and ferritin levels in patients with thalassemia major and intermedia in Southern Iran. Iran Red Crescent Med J. 2015;17(7). e28343. doi: 10.5812/ircmj.17(5)2015.28343. [PubMed: 26421179]. [PubMed Central: PMC4583770].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments